Roche

With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
With Rising Drug Prices a Concern, Some Companies Enact Their Own Control Plans
BioSpace
drug pricing
Roche
Eli Lilly
Amgen
Alnylam
Sanofi
Flag link:
Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report
Roche aims to 'underwhelm' with risdiplam price as it enters SMA rivalry with Biogen, Novartis — report
Endpoints
SMA
Roche
risdiplam
Biogen
Novartis
drug pricing
Flag link:
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
New MS Trial Will be First to Compare Stem Cell Therapy with Best Available Biologics
Xtalks
stem cells
MS
multiple sclerosis
NIH
AHSCT
Biogen
Tysabri
Sanofi
Lemtrada
Roche
Ocrevus
Rituxan
Flag link:
Roche Pays $40M to Use Amunix Pharma’s Half-Life Extension Tech
Roche Pays $40M to Use Amunix Pharma’s Half-Life Extension Tech
Xconomy
Roche
Amunix
R&D
half-life extension
XTEN
Flag link:
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Merck-partnered biotech hands Roche its half-life extension tech as it pivots to immuno-oncology
Endpoints
Roche
immuno-oncology
Amunix
Merck
CAR-T
Flag link:
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Despite secret discount, Roche's Tecentriq hits NICE roadblock in small-cell lung cancer
Fierce Pharma
Roche
Tecentriq
NICE
UK
Small-Cell Lung Cancer
Flag link:
Top Biopharma M&As in 2019
Top Biopharma M&As in 2019
BioSpace
M&A
Bristol-Myers Squibb
Celgene
AbbVie
Allergan
Roche
Spark Therapeutics
Novartis
The Medicines Company
Alkermes
Rodin Therapeutics
Sumitomo Dainippon
Roivant
Flag link:
An immuno-oncology triplet from Roche shows promise in mouse models of several tumors
An immuno-oncology triplet from Roche shows promise in mouse models of several tumors
Fierce Biotech
Roche
targeted antibodies
breast cancer
colon cancer
skin cancer
Flag link:
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Roche Puts Up Historic $1.15B for Sarepta Duchenne Gene Therapy Deal
Xconomy
Roche
Sarepta Therapeutics
FDA
Duchenne Muscular Dystrophy
SRP-9001
Flag link:
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Amgen, Allergan join Rituxan biosimilar challenge with FDA filing
Pharmaforum
Amgen
Allergan
biosimilar
Roche
Rituxan
Flag link:
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Roche's Ocrevus, GSK's Dovato ads top November TV spending charts—behind Humira, of course
Fierce Pharma
drug ads
television ads
Roche
Ocrevus
GSK
Dovato
AbbVie
Humira
Flag link:
WHO Prequalifies its First Biosimilar
WHO Prequalifies its First Biosimilar
RAPS.org
WHO
biosimilars
Samsung Bioepis
Ontruzant
Roche
Herceptin
breast cancer
Flag link:
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
Arcus and Roche Partner on Colorectal and Pancreatic Cancer Trials
BioSpace
Roche
Genentech
Arcus Biosciences
clinical trials
colorectal cancer
pancreatic cancer
AB928
Flag link:
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
ESMO I-O: Roche silences Tecentriq doubters with latest lung cancer analysis
Fierce Pharma
ESMO
Roche
Tecentriq
non-small cell lung cancer
Flag link:
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Novartis top of pile in European pharma in 2020, say Jefferies analysts
Pharmaforum
Novartis
Europe
GSK
Sanofi
AstraZeneca
Roche
Flag link:
Roche's $4.8B deal for Spark cleared by FTC after long delay
Roche's $4.8B deal for Spark cleared by FTC after long delay
Biopharma Dive
Roche
Spark Therapeutics
M&A
FTC
Flag link:
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Could Spark Therapeutics’ merger with Roche finally get the go-ahead?
Pharmaforum
Spark Therapeutics
Roche
UK
M&A
CMA
Flag link:
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Roche’s fixed-dose subcutaneous combination of Perjeta and Herceptin comparable to intravenous formulations in people with HER2-positive breast cancer
Pharmaceutical Business Review
Roche
Perjeta
Herceptin
HER2+ breast cancer
SABCS
breast cancer
Flag link:
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
SABCS: Merck's Keytruda notches win in triple-negative breast cancer as Roche's Tecentriq falls short
Fierce Pharma
Merck
Ketyruda
Roche
Tecentriq
immuno-oncology
SABCS
triple-negative breast cancer
Flag link:
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
SABCS: Roche's Perjeta builds case as add-on to Herceptin with new analysis
Fierce Pharma
Roche
breast cancer
Herceptin
Perjeta
biosimilars
SABCS
Flag link:

Pages